Olfactory Dysfunction, Wellbeing
Conditions
Keywords
Olfactory testing, Smell dysfunction, Psychological health, Randomized clinical trial, Patient-centered care, Access to care
Brief summary
Smell dysfunction is frequent yet neglected. The sense of smell plays a crucial role in signaling disease, safety, and overall quality of life. However, the significance of a functional sense of smell in terms of health and well-being is often overlooked until one experiences a loss of smell due to injury or disease. Research demonstrates that individuals are often not self-aware of their smell dysfunction (i.e. they do not spontaneously report smell dysfunction as a symptom), especially if the changes are gradual, as in normal aging. Patients with smell dysfunction experience a marked reduction in quality of life, poor mental health, nutritional health, and brain health as well as increased 5- and 10-year mortality in older adults. This study explores whether or not enabling healthcare providers to offer resources and guidance on coping strategies for smell dysfunction improves health and wellbeing in those who experience it.
Detailed description
The investigators will recruit participants in cycles for in person or remote participation. Each cycle is characterized by an initial assessment, intervention deployment (smell testing), post-intervention evaluation, 1-month and 6-month follow-ups via survey, text or phone to assess post-intervention psychological health and connection to care for smell dysfunction. The research team will assess odor detection, intensity, identification, pleasantness and discrimination. Based on the cut-offs determined prior to the beginning of data collection, the investigators will prospectively assign a participant to the smell dysfunction group or to the normosmia (no smell dysfunction) group. Based on this diagnostic intervention, participants with smell dysfunction will receive patient-centered information and education about i) community engagement with individuals with smell loss, ii) available counseling and iii) medical support. At the end of the 1-month and 6-month follow-up periods, the investigators will assess effectiveness of the intervention using pre-post comparisons to determine whether individuals taking a smell test felt improvements in their psychological health and whether they have contacted a provider and/or followed up with a visit. Sessions may include multiple surveys/instruments depending on the session number. Specifically, emotional ratings and demographic information will be collected by means of either a paper - or computer-based questionnaire. A survey to measure psychological health and quality of life will be given to participants, as well as a questionnaire to measure depression, which is associated with smell dysfunction. Participants will answer questions about how they are feeling and how ready they are to contact a healthcare provider. The specific smell tests that will be given to participants will be either SCENTinel, NIH Toolbox, Arohma, or the B-SIT test. Other Follow-Up Questions include ones regarding access to care, contacting a provider, seeing a provider, and satisfaction with care.
Interventions
Participants with smell dysfunction will receive patient-centered information and education about i) community engagement with individuals with smell loss, ii) available counseling and iii) medical support.
Sponsors
Study design
Intervention model description
Olfactory data will be collected with six standardized smell tests in the in-person cohort and four standardized smell tests in the remote cohort. The research team will assess odor detection, intensity, identification, pleasantness and discrimination. Based on the cut-off scores determined before the beginning of data collection, the investigators will assign a participant to the smell dysfunction group or to the normosmia (non-smell dysfunction) group. Based on this diagnostic intervention, participants with smell dysfunction will receive patient-centered information and education about i) community engagement with individuals with smell loss, ii) available counseling and iii) medical support.
Eligibility
Inclusion criteria
\- Can read and understand English and have access to a reliable internet connection and a smart device or computer for the duration of the experimental sessions, unless they are part of community events in which smart devices are provided
Exclusion criteria
\- Known intolerance or allergy to any of the odor stimuli used
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measuring depression symptoms using the PHQ-9 score | PHQ-9 is completed at baseline, during 1 month follow-up session, and during the 6 month follow-up. | The PHQ-9 is a screening measure of depressive symptoms. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measuring health-related quality of life using the SF-12 survey. | SF-12 is completed at baseline, during 1 month follow-up session, and during the 6 month follow-up. | The SF-12 is a screening measure of health-related quality of life. |
| Measuring self-reported health perception using a How do you feel? 0-100 Visual Analogue Scale (VAS). | VAS is completed at baseline, during 1 month follow-up session, and during the 6 month follow-up. | How do you feel? VAS is a self-reported measure of health perception. |
| Effectiveness of implementation (to contact a healthcare provider for smell dysfunction within up to 6 months from smell testing). | Evaluated during 1 month and 6 month follow ups | Participants are asked a Yes or No question about whether they contacted a healthcare provider. The investigators will examine the proportion of participants connecting with a healthcare provider for smell dysfunction. |
Countries
United States